Researchers watch how new prostate cancer drug works in everyday clinics

NCT ID NCT07093801

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Dec 17, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This study follows 300 men with advanced prostate cancer that no longer responds to hormone therapy. Participants receive a standard treatment called lutetium-177 vipivotide tetraxetan, which delivers radiation directly to cancer cells. The goal is to see how well it works in real-world settings, not to test a new drug. No extra treatments or procedures are given beyond normal care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Alessandria, AL, 15121, Italy
Novartis Investigative Site
RECRUITING

Asti, AT, 14100, Italy
Novartis Investigative Site
RECRUITING

Bergamo, BG, 24127, Italy
Novartis Investigative Site
RECRUITING

Brescia, BS, 25123, Italy
Novartis Investigative Site
RECRUITING

Catania, CT, 95123, Italy
Novartis Investigative Site
RECRUITING

Meldola, FC, 47014, Italy
Novartis Investigative Site
RECRUITING

Cona, FE, 44124, Italy
Novartis Investigative Site
RECRUITING

Foggia, FG, 71122, Italy
Novartis Investigative Site
RECRUITING

Florence, FI, 50134, Italy
Novartis Investigative Site
RECRUITING

Genova, GE, 16128, Italy
Novartis Investigative Site
RECRUITING

Genova, GE, 16132, Italy
Novartis Investigative Site
RECRUITING

Latina, LT, 04100, Italy
Novartis Investigative Site
RECRUITING

Province of Macerata, MC, 62100, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20133, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20141, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20162, Italy
Novartis Investigative Site
RECRUITING

Rozzano, MI, 20089, Italy
Novartis Investigative Site
RECRUITING

Palermo, PA, 90146, Italy
Novartis Investigative Site
RECRUITING

Perugia, PG, 06129, Italy
Novartis Investigative Site
RECRUITING

Pisa, PI, 56126, Italy
Novartis Investigative Site
RECRUITING

Aviano, PN, 33081, Italy
Novartis Investigative Site
RECRUITING

Rionero in Vulture, PZ, 85028, Italy
Novartis Investigative Site
RECRUITING

Reggio Emilia, RE, 42123, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00128, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00152, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00168, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00189, Italy
Novartis Investigative Site
RECRUITING

La Spezia, SP, 19121, Italy
Novartis Investigative Site
RECRUITING

Torino, TO, 10128, Italy
Novartis Investigative Site
RECRUITING

Mestre, VE, 30174, Italy
Novartis Investigative Site
RECRUITING

Negrar, VR, 37024, Italy
Novartis Investigative Site
RECRUITING

Naples, 80131, Italy

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER